Literature DB >> 33764814

Prevalence and longitudinal correlates of recent exposure to fentanyl among HIV-positive people who use unregulated drugs during a community-wide overdose crisis.

Soroush Moallef1,2, Ekaterina Nosova1,3, Seonaid Nolan1,3, Nadia Fairbairn1,3, Jane Loh1,4, Kanna Hayashi2, M-J Milloy1,3.   

Abstract

The United States and Canada are experiencing an opioid overdose crisis driven largely by exposure to fentanyl (a potent synthetic opioid), with little known about fentanyl exposure among HIV-positive people who use unregulated drugs (PWUD). We sought to estimate the prevalence and correlates of fentanyl exposure among a community-recruited sample derived from a prospective cohort study of HIV-positive PWUD in Vancouver, Canada. Generalized linear mixed-effects analyses were used to identify longitudinal factors associated with a fentanyl-positive urine drug screen test. Between June 2016-November 2017, 456 participants were recruited and contributed 1007 observations. At baseline, 96% of participants were ART-exposed, 72% had an HIV viral load (VL) <50 copies/mL and 21% had a fentanyl-positive test. Longitudinally, fentanyl-positive tests were characterized by: younger participant age (Adjusted Odds Ratio [AOR] = 0.45), recent non-fatal overdose (AOR = 2.30), engagement in opioid agonist therapy (AOR = 1.91), and at least daily heroin injection (AOR = 11.27). CD4+ cell count was negatively associated with fentanyl urine positivity (AOR = 0.92) (all p < 0.05). We identified several risk factors for overdose linked to fentanyl exposure among this sample, although no link with HIV treatment engagement or detectable HIV VL. Innovative strategies are needed to reduce the harmful effects of the contaminated unregulated drug supply experienced by PWUD.

Entities:  

Keywords:  Fentanyl exposure; HIV-positive; overdose; urine drug screen

Mesh:

Substances:

Year:  2021        PMID: 33764814      PMCID: PMC8463637          DOI: 10.1080/09540121.2021.1874272

Source DB:  PubMed          Journal:  AIDS Care        ISSN: 0954-0121


  36 in total

1.  Illicit drug use and HIV-1 disease progression: a longitudinal study in the era of highly active antiretroviral therapy.

Authors:  Gregory M Lucas; Michael Griswold; Kelly A Gebo; Jeanne Keruly; Richard E Chaisson; Richard D Moore
Journal:  Am J Epidemiol       Date:  2006-01-04       Impact factor: 4.897

2.  Early immunologic and virologic responses to highly active antiretroviral therapy and subsequent disease progression among HIV-infected injection drug users.

Authors:  S H Mehta; G Lucas; J Astemborski; G D Kirk; D Vlahov; N Galai
Journal:  AIDS Care       Date:  2007-05

Review 3.  Self-report among injecting drug users: a review.

Authors:  S Darke
Journal:  Drug Alcohol Depend       Date:  1998-08-01       Impact factor: 4.492

4.  Initial results of a drug checking pilot program to detect fentanyl adulteration in a Canadian setting.

Authors:  Kenneth W Tupper; Karen McCrae; Ian Garber; Mark Lysyshyn; Evan Wood
Journal:  Drug Alcohol Depend       Date:  2018-07-24       Impact factor: 4.492

Review 5.  Caring for patients with opioid use disorder in the hospital.

Authors:  Joseph H Donroe; Stephen R Holt; Jeanette M Tetrault
Journal:  CMAJ       Date:  2016-09-19       Impact factor: 8.262

Review 6.  Adherence to antiretroviral medications among persons who inject drugs in transitional, low and middle income countries: an international systematic review.

Authors:  Jonathan Feelemyer; Don Des Jarlais; Kamyar Arasteh; Anneli Uusküla
Journal:  AIDS Behav       Date:  2015-04

Review 7.  Clinical use of methadone.

Authors:  Cherokee Layson-Wolf; Jean-Venable Goode; Ralph E Small
Journal:  J Pain Palliat Care Pharmacother       Date:  2002

8.  An analysis of the duration of fentanyl and its metabolites in urine and saliva.

Authors:  J H Silverstein; M F Rieders; M McMullin; S Schulman; K Zahl
Journal:  Anesth Analg       Date:  1993-03       Impact factor: 5.108

9.  Known fentanyl use among clients of harm reduction sites in British Columbia, Canada.

Authors:  Mohammad Karamouzian; Kristi Papamihali; Brittany Graham; Alexis Crabtree; Christopher Mill; Margot Kuo; Sara Young; Jane A Buxton
Journal:  Int J Drug Policy       Date:  2020-01-18

10.  Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes.

Authors:  Bruno Ledergerber; Jens D Lundgren; A Sarah Walker; Caroline Sabin; Amy Justice; Peter Reiss; Cristina Mussini; Ferdinand Wit; Antonella d'Arminio Monforte; Rainer Weber; Gregory Fusco; Schlomo Staszewski; Matthew Law; Robert Hogg; Fiona Lampe; M John Gill; Francesco Castelli; Andrew N Phillips
Journal:  Lancet       Date:  2004 Jul 3-9       Impact factor: 79.321

View more
  2 in total

1.  The synthetic opioid fentanyl increases HIV replication and chemokine co-receptor expression in vitro.

Authors:  Ling Kong; Mohamed Tarek M Shata; Jennifer L Brown; Michael S Lyons; Kenneth E Sherman; Jason T Blackard
Journal:  J Neurovirol       Date:  2022-08-17       Impact factor: 3.739

2.  Day-to-day impact of COVID-19 and other factors associated with risk of nonfatal overdose among people who use unregulated drugs in five cities in the United States and Canada.

Authors:  Soroush Moallef; Becky L Genberg; Kanna Hayashi; Shruti H Mehta; Gregory D Kirk; JinCheol Choi; Kora DeBeck; Michele Kipke; Richard D Moore; Marianna K Baum; Steven Shoptaw; Pamina M Gorbach; Brian Mustanski; Marjan Javanbakht; Susanne Siminski; M-J Milloy
Journal:  Drug Alcohol Depend       Date:  2022-09-15       Impact factor: 4.852

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.